Novo Nordisk A/S(NVO)NASDAQ
Stock Overview & Analysis
Novo Nordisk A/S (NVO) quick overview 2026-02-20
- The stock is currently trading at $47.42, experiencing a short-term pullback within a declining trend—trading below its 50-day average while below the 200-day.
- Analysts appear optimistic, with a 1-year price target of $53.86 (13.6% upside).
- Volatility is elevated (64.75% annualized), implying wide price swings.
- The fundamental story is nuanced: solid revenue growth (-7.60% YoY) alongside significant competitive pressures.
Here's What You Need to Know Right Now
Concise, actionable context
Novo Nordisk A/S - Historical Price & Volume
Market Cap
Enterprise Value: $322.77B
P/E Ratio
Forward P/E: 14.18
Revenue Growth
Year over Year
Analyst Target
+13.6% upside potential
Key Investor Questions
Clarity over jargon
- Technicals say: Neutral (RSI 33.07)
- Fundamentals say: Challenging (declining revenue trends)
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
- $130.96B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
Trading Range
Over the past year, the stock traded between $43.08 and $93.80—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility
With 64.75% annualized volatility and β=0.40, the stock exhibits low sensitivity to market moves—suitable for investors comfortable with active risk management.
Ownership Snapshot
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment
Latest News
Recent headlines and coverage
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200
These two healthcare stocks are likely headed higher from their current prices.
GLP-1 wars: Wegovy maker challenges knock-off weight loss drug companies
Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.
Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside
HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the company reports earnings this month.
Novo Nordisk Stock Investors Just Got Great News From Eli Lilly
But it's good news for Eli Lilly, too.
Is Pfizer Stock an Underrated Healthcare Investment Play?
Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success.
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
Wall Street is overly focused on GLP-1 drugs even as this medical device maker continues to thrive.
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday trading
European equities traded in the US as American depositary receipts edged up 0.1% to 1,845.20 on the
Prothena Corporation plc Q4 2025 Earnings Call Summary
Moby summary of Prothena Corporation plc's Q4 2025 earnings call
Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth
Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 11, Ascendis Pharma reported that it nearly doubled its total revenue for 2025 to €720 million, fueled by the rapid global adoption of its core endocrinology products. Q4 was particularly significant, as the company achieved […]
Frequently Asked Questions
Common investor questions about Novo Nordisk A/S
Novo Nordisk A/S (NVO) is currently trading at $47.42. The RSI (14-day) is at 33.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $53.86 implies 13.6% upside from current levels. Volatility is high at 64.7% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Novo Nordisk A/S (NVO): The trailing P/E ratio is 13.27, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 14.18. The PEG ratio is 4.13, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 7.01. Price-to-Sales is 0.70. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 11 analysts covering NVO, the consensus price target is $53.86. This represents a 13.6% upside from the current price of $47.42. The range spans from a low target of $41.70 to a high target of $69.25, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Novo Nordisk A/S (NVO) pays a dividend with a current yield of approximately 3.92%. The annualized dividend rate is $11.70 per share. The payout ratio is 50.4%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-03-30.
Key risks for Novo Nordisk A/S (NVO) investors include: 1. High volatility (64.7% annualized)—the stock can experience significant daily price swings. 2. Declining revenue (-7.6% YoY), indicating potential business headwinds. 3. Elevated short interest (94.0% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Novo Nordisk A/S's (NVO) current debt and financial health profile: Total debt stands at $130.96B. The debt-to-equity ratio is 67.49, which is moderate and generally manageable for most companies. The current ratio is 0.80, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.54. The company holds $26.96B in cash and equivalents. Free cash flow is positive at $376.88M, providing a cushion for debt servicing and shareholder returns.